• Clinical Assistant Professor, Global Health
  • Lead, Microneedle Patch Research, Inventprise
  • Vaccine Research, Development & Programs, Inventprise

Box 359931
Seattle, WA
United States

Phone Number: 
206-427-8256
Fax: 
Select from the following:
Biography 

Dr. Toritse Orubu a global vaccine leader with a multi-disciplinary background in vaccine R&D, immunization, device & technologies, public health, infectious disease research, implementation science and MNCH.

Dr. Orubu is currently Lead, Microneedle Patch Research, Development and Programs, Vaccines at Inventprise, a Biotech company based in Seattle. Prior to this role, Dr. Orubu was a Fellow at the Bill and Melinda Gates Foundation where he supported Vaccine Development (CMC). His work at the Gates Foundation involved strategic investments on novel vaccine formulations, technologies, devices including advocacy and scientific support on Ebola.

Prior to joining BMGF, Dr. Orubu was a Senior Manager, New Vaccine Introduction at the Clinton Health Access Initiative (CHAI), where he led the successful introduction of pentavalent vaccines to over 8 million children in Nigeria.

Dr. Orubu holds a PhD in Clinical Medicine, University of Oxford (UK) where he holds a patent for his work on a novel recombinant pox viral (MVA) for the development of vaccines against malaria, universal flu, HIV and TB. Dr Orubu has published many peer reviewed papers and co-authored two books.

Education 
  • PhD (University of Oxford)
  • MSc (University of London (UK))
  • MPH (University of Aberdeen (UK))
  • BSc (University of Benin)
Country Affiliations 
Health Topics 
  • Delivery Logistics
  • Diarrheal Diseases
  • Disease Surveillance
  • Drug and Vaccine Development
  • Ebola
  • Health Policy and Advocacy
  • Immunizations
  • Infectious Diseases
  • Malaria
  • Mobile Health (mHealth)
  • Molecular Immunology
  • Neglected Diseases, Tropical Medicine (incl. Parasites)
  • Research
  • Viruses
Publications 

Peyraud N,Zehrung D, Jarrahian C, Frivold C, Orubu T, Giersing B.Potential use of microarray patches for vaccine delivery in low- and middle-income https://doi.org/10.1016/j.vaccine.2019.03.035

Naif Khalaf Alharbi a,b,∗, Alexandra J. Spencer a, Ahmed M. Salmana, Claire M. Tullya, Senthil k. Toritse Orubu et. al (2016) Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine 34 (2016) 49–55 http://dx.doi.org/10.1016/j.vaccine.2015.11.028

Orubu T, Alharbi NK, Lambe T, Gilbert SC, Cottingham MG (2012) Expression and immunogenicity of transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS ONE 7(6): e40167. doi:10.1371/journal.pone.0040167

Strengthening Health Systems in Nigeria: Workshop proceedings on Evidence Based Policy Making Project. This book is published by West African Book Publishers Limited for The Nigerian Academy of Science, June 2009 ISBN: 978-978-153-415-7

Reducing Child Mortality in Nigeria: Workshop proceedings on Evidence Based Policy Making Project. This book is published by West African Book Publishers Limited for The Nigerian Academy of Science, February, 2009 ISBN: 978– 978– 153–399–0